|1.||Wiethoff, Andrea J: 7 articles (06/2014 - 09/2004)|
|2.||Caravan, Peter: 5 articles (12/2015 - 05/2008)|
|3.||Botnar, Rene M: 5 articles (06/2014 - 03/2005)|
|4.||Spuentrup, Elmar: 5 articles (09/2008 - 09/2004)|
|5.||Katoh, Marcus: 5 articles (09/2008 - 09/2004)|
|6.||Parsons, Edward C: 5 articles (08/2007 - 09/2004)|
|7.||Günther, Rolf W: 4 articles (09/2008 - 03/2005)|
|8.||Buecker, Arno: 4 articles (08/2007 - 09/2004)|
|9.||Graham, Philip B: 3 articles (08/2007 - 09/2004)|
|10.||Ay, Ilknur: 2 articles (12/2015 - 06/2010)|
|1.||Body Weight (Weight, Body)
03/01/2011 - "Utilizing an equivalent dose on a Gd ion per body weight basis, signal-to-noise, contrast-to-noise, and CE were greater for EP-2104R at all time points postcontrast, yielding overall statistically significantly greater levels of all 3 parameters with the latter. "
05/01/2007 - "MRI was then performed before and up to 120 minutes after injection of 4 micromol/kg body weight EP-2104R. "
|2.||Brain Neoplasms (Brain Tumor)
03/22/2005 - "The aim of this study was to investigate the novel fibrin-specific contrast agent EP-2104R for molecular targeted MR imaging of coronary thrombosis and pulmonary emboli. "
11/01/2007 - "Molecular MR imaging using the fibrin-targeted contrast agent EP-2104R allows selective visualization of human clot material in a model of coronary thrombosis in swine."
12/16/2015 - "Mn-FBP provided equivalent thrombus enhancement to the state of the art Gd analogue, EP-2104R, in a rat model of arterial thrombosis. "
09/14/2004 - "In-stent thrombi: in-stent thrombosis was observed in all stents after EP-2104R. "
09/14/2004 - "Free-breathing, navigator-gated 3D coronary MR angiography and thrombus imaging were performed (1) before and after stent placement and (2) before and after EP-2104R. "
06/01/2014 - "Eighteen mice were scanned at each time point pre and 2 hours post injection of EP-2104R (8.0 μmol/kg) with 12 mice at each time point used to correlate fibrin contrast uptake with thrombus' histological stage and fibrin content. "
06/01/2010 - "The concentration of gadolinium in the thrombus after EP-2104R was 18 times that in the blood pool. "
10/01/2012 - "EP-2104R transiently enhanced both tumor core and tumor periphery, but only the enhancement in the tumor periphery persisted even 90 minutes after EP-2104R administration. "
10/01/2012 - "The persistent enhancement observed in the tumor periphery with EP-2104R is likely a result of its fibrin-specific binding rather than its size and demonstrates the feasibility of EP-2104R for molecular imaging of fibrin in tumor stroma."
10/01/2012 - "The half-life of EP-2104R in the tumor periphery (103 ± 18 minutes) is significantly longer (P < 0.05) than that of either Gd-DTPA (29.6 ± 2.4 minutes) or CLP (42.4 ± 1.5 minutes), but the rate of clearance is similar for all the 3 probes from the tumor core. "
03/01/2011 - "Maximum tumor contrast-to-noise and CE both occurred at 1 minute versus at 5 minutes following administration of Gd DTPA versus EP-2104R, respectively. "
|2.||Gadolinium DTPA (Magnevist)
|2.||Heterologous Transplantation (Xenotransplantation)